Approval · Notice of Compliance 27473 · 2022
DUTASTERIDE: Notice of Compliance 27473
Issued January 25, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27473
- Date
- January 25, 2022
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Companies
- Canadian reference product
- AVODART (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DUTASTERIDE | 02443058 | Marketed |
Medicinal ingredients
- DUTASTERIDE 0.5 MG per CAP